Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
McKesson
Dow
Colorcon
Mallinckrodt

Last Updated: May 20, 2022

UBRELVY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Ubrelvy, and when can generic versions of Ubrelvy launch?

Ubrelvy is a drug marketed by Allergan and is included in one NDA. There are five patents protecting this drug.

This drug has eighty-eight patent family members in forty-one countries.

The generic ingredient in UBRELVY is ubrogepant. One supplier is listed for this compound. Additional details are available on the ubrogepant profile page.

DrugPatentWatch® Generic Entry Outlook for Ubrelvy

Ubrelvy will be eligible for patent challenges on December 23, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 30, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for UBRELVY
International Patents:88
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 20
Clinical Trials: 5
Patent Applications: 73
Drug Prices: Drug price information for UBRELVY
What excipients (inactive ingredients) are in UBRELVY?UBRELVY excipients list
DailyMed Link:UBRELVY at DailyMed
Drug patent expirations by year for UBRELVY
Drug Prices for UBRELVY

See drug prices for UBRELVY

DrugPatentWatch® Estimated Generic Entry Opportunity Date for UBRELVY
Generic Entry Date for UBRELVY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for UBRELVY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganPhase 4
Messoud Ashina, MDPhase 4
AllerganPhase 3

See all UBRELVY clinical trials

US Patents and Regulatory Information for UBRELVY

UBRELVY is protected by five US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of UBRELVY is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting UBRELVY

Tablet formulation for CGRP active compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH HEADACHE, WITH OR WITHOUT AURA IN ADULTS

Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

FDA Regulatory Exclusivity protecting UBRELVY

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-001 Dec 23, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Allergan UBRELVY ubrogepant TABLET;ORAL 211765-002 Dec 23, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for UBRELVY

When does loss-of-exclusivity occur for UBRELVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 15214502
Estimated Expiration: See Plans and Pricing

Patent: 19226239
Estimated Expiration: See Plans and Pricing

Patent: 21245229
Estimated Expiration: See Plans and Pricing

Canada

Patent: 37315
Estimated Expiration: See Plans and Pricing

Patent: 37942
Estimated Expiration: See Plans and Pricing

China

Patent: 5939715
Estimated Expiration: See Plans and Pricing

Patent: 5960397
Estimated Expiration: See Plans and Pricing

Patent: 2022818
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 02188
Estimated Expiration: See Plans and Pricing

Patent: 02210
Estimated Expiration: See Plans and Pricing

Patent: 02211
Estimated Expiration: See Plans and Pricing

Patent: 02564
Estimated Expiration: See Plans and Pricing

Patent: 37412
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 32218
Estimated Expiration: See Plans and Pricing

Israel

Patent: 6828
Estimated Expiration: See Plans and Pricing

Japan

Patent: 91669
Estimated Expiration: See Plans and Pricing

Patent: 66490
Estimated Expiration: See Plans and Pricing

Patent: 17505306
Estimated Expiration: See Plans and Pricing

Patent: 19108366
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 16010169
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 96578
Estimated Expiration: See Plans and Pricing

Patent: 19123406
Estimated Expiration: See Plans and Pricing

Saudi Arabia

Patent: 6371613
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 160113296
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering UBRELVY around the world.

Country Patent Number Title Estimated Expiration
Canada 2937942 COMBINAISONS A DOSE FIXE DE COMPOSES ANTIVIRAUX (FIXED-DOSE COMBINATIONS OF ANTIVIRAL COMPOUNDS) See Plans and Pricing
Saudi Arabia 516371613 CGRP صيغة قرص لمركبات نشطة تجاه (Tablet Formulation for CGRP-Active Compounds) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2015119919 See Plans and Pricing
Poland 2821407 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Express Scripts
Johnson and Johnson
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.